These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36082084)

  • 21. The Impact of Neoadjuvant Chemotherapy on Patients With T1N0M0 Triple-Negative and HER-2 Positive Breast Cancer: A Retrospective Analysis Based on the SEER Database.
    Cheng H; Dai Q; Liu G; Tong X; Wang Y
    Clin Breast Cancer; 2024 Oct; 24(7):e593-e599. PubMed ID: 38890023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy.
    Ho AY; Gupta G; King TA; Perez CA; Patil SM; Rogers KH; Wen YH; Brogi E; Morrow M; Hudis CA; Traina T; McCormick B; Powell SN; Robson ME
    Cancer; 2012 Oct; 118(20):4944-52. PubMed ID: 22392492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
    Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
    BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of prognostic and treatment between T1a and T1b glottic cancer: a propensity score-matched SEER database analysis.
    Fang L; Tuohuti A; Shi L; Chen X
    Eur Arch Otorhinolaryngol; 2023 Jul; 280(7):3313-3322. PubMed ID: 37039896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes in patients with small node-negative invasive breast cancer.
    Bao J; Donovan C; Amersi F; Zhang X; Giuliano AE; Chung A
    Breast J; 2019 Jul; 25(4):638-643. PubMed ID: 31079425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study.
    Schreiber AR; Kagihara J; Eguchi M; Kabos P; Fisher CM; Meyer E; Molina E; Kondapalli L; Bradley CJ; Diamond JR
    Breast Cancer Res Treat; 2022 Jan; 191(2):389-399. PubMed ID: 34705147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?
    Kelly CM; Pritchard KI; Trudeau M; Andreopoulou E; Hess K; Pusztai L
    Ann Oncol; 2011 Nov; 22(11):2387-2393. PubMed ID: 21406473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
    Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
    Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
    He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
    Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Factors and Models for Elderly (≥70 Years Old) Primary Operable Triple-Negative Breast Cancer: Analysis From the National Cancer Database.
    Tang Z; Ji Y; Min Y; Zhang X; Xu W; Zhao L; Zhang J; Long L; Feng J; Wen Y
    Front Endocrinol (Lausanne); 2022; 13():856268. PubMed ID: 35370936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort.
    Rouanet P; Roger P; Rousseau E; Thibault S; Romieu G; Mathieu A; Cretin J; Barneon G; Granier M; Maran-Gonzalez A; Daures JP; Boissiere F; Bibeau F
    Cancer Med; 2014 Feb; 3(1):134-42. PubMed ID: 24407937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nomogram for Predicting Overall Survival and Assessing the Survival Benefit of Adjuvant Treatment in pT1-2N0M0 Triple-Negative Breast Cancer: A Surveillance, Epidemiology, and End Results-Based Study.
    Mao Q; Liu S; Lv M; Sun Y; Zhang C; Li L
    Front Oncol; 2021; 11():663621. PubMed ID: 35284333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy.
    Fu WF; Chen QX; Wang XX; Zhang J; Song CG
    Front Oncol; 2020; 10():1753. PubMed ID: 33102205
    [No Abstract]   [Full Text] [Related]  

  • 34. The Effect of Adjuvant Treatment in Small Node-negative HER2-positive Breast Cancer: Which Subgroup Will Benefit?
    Lin H; Zheng H; Ge C; Wang Q; Tang W; Zhang X; Zhou S; Jin X; Xu X; Du J; Fu J
    Clin Breast Cancer; 2020 Dec; 20(6):503-510. PubMed ID: 32653474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant Chemotherapy for Low-Clinical-Risk Breast Cancer Defined by Modified Version of Adjuvant! Online: A Propensity Score Matched SEER Analysis.
    Huang J; Wu Z; Zhang Z; Li J; Li Y; Ren G
    Breast Care (Basel); 2021 Apr; 16(2):156-162. PubMed ID: 34012370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant chemotherapy could benefit early-stage ER/PR positive mucinous breast cancer: A SEER-based analysis.
    Gao HF; Li WP; Zhu T; Yang CQ; Yang M; Zhang LL; Ji F; Cheng MY; Li JQ; Wang K
    Breast; 2020 Dec; 54():79-87. PubMed ID: 32947149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant chemotherapy in small node-negative triple-negative breast cancer.
    Steenbruggen TG; van Werkhoven E; van Ramshorst MS; Dezentjé VO; Kok M; Linn SC; Siesling S; Sonke GS
    Eur J Cancer; 2020 Aug; 135():66-74. PubMed ID: 32554215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.
    Du ZL; Wang Y; Wang DY; Zhang L; Bian ZM; Deng Y; Xu CS; Lin DC; Xie L; Jia Y; Gao JD; Zhang BL
    Breast Cancer Res Treat; 2020 Sep; 183(2):429-438. PubMed ID: 32647940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome.
    Lee AK; Loda M; Mackarem G; Bosari S; DeLellis RA; Heatley GJ; Hughes K
    Cancer; 1997 Feb; 79(4):761-71. PubMed ID: 9024714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.